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remission up to one year after transplant. In conclusion, the pre-
liminary results in indolent Non-Hodgkin’s lymphoma including
CLL and MCL are encouraging with 12 of 16 patients in sustained
complete remission. Prior therapy is likely an important factor in
donor engraftment and the incidence of severe GVHD has been
low. A GVL effect is suggested but the relationship with GVHD is
uncertain. The efﬁcacy of Rituximab in the post-transplant setting
is intriguing and warrants further investigation. This strategy ex-
tends treatment options for advanced or refractory low grade
B-cell lymphoid malignancies. Patient referral prior to the devel-
opment of refractory disease should be considered.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION
Wagner, J.E., Brunstein, C., Barker, J. Blood and Marrow Transplant
Program, University of Minnesota, Minneapolis, MN
Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable
donors, reducing the risks of acute and chronic graft-versus-host
disease (GVHD) and improving survival. Cell dose, however, has
clearly been identiﬁed as a major limitation, often preventing the
consideration of UCB for adult recipients. Recipients of 2.5 
107 nucleated cells/kg have slow hematopoietic recovery and sig-
niﬁcantly lower incidence of engraftment. Therefore, we explored
the potential of infusing two partially HLA matched units to
augment cell dose. The underlying hypothesis is that the addition
of the second unit will enhance engraftment and speed of hema-
topoietic recovery. Thirty-one adult and adolescent patients [me-
dian age 24 years (range: 13-53); median weight 73 kg (range:
48-120)] with high-risk hematologic malignancy were transplanted
with two partially HLA-matched UCB units after myeloablative
conditioning. Patients had AML (n  15), ALL (n  12), CML (n
 3) or NHL (n  1). The median total infused dose 3.7  107
NC/kg (range 1.1-6.3) and 4.9  105 CD34/kg (range, 0.9-14.5).
All patients engrafted at a median of 23 days (range 14-41) with
one unit predominating. No factor (nucleated cell dose, CD34
cell dose, HLA-match, ABO, sex, order of infusion) predicted
which unit would predominate. Incidence of platelet recovery
(50,000/L) was 73% (95% CI, 51-95) at day 180. Incidence of
grades II-IV and III-IV acute graft-versus-host disease (GVHD)
was 65% (95% CI, 42-88) and 17% (95% CI, 2-32) at day 100.
Disease-free survival is 72% at 1 year for patients transplanted in
CR with no relapse in this cohort (median follow up: 1.2 years).
These data suggest that 1) double unit UCBT is safe with one unit
predominating over time, 2) double unit UCBT extends the ap-
plication of adults to nearly all adults and adolescents and 3)
survival exceeds historical data with a single UCB unit. Validation
studies at other centers are in progress.
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UNRELATED SINGLE CORD BLOOD TRANSPLANTS SUPPORTED BY
CO-INFUSION OF A LOW NUMBER OF MOBILIZED PERIPHERAL BLOOD
HIGHLY PURIFIED CD34 CELLS FROM A THIRD PARTY DONOR AFTER
LOW TOXICITY MYELOABLATIVE CONDITIONING
Fernandez, M.N. Hospital Universitario Puerta de Hierro, Madrid,
Spain
Late and low rate engraftment and toxicity are recognized factors
for the early TRM of unrelated CBT that has jeopardized its wide
use mostly in adults. Aside of the own nature of CB stem cells and
HLA mismatches, low cell content in the transplanted product is a
factor for graft failure and late engraftment. Our approach to solve
this problem is co-infusion of the best available CB unit (3/6
HLA mm and TNC 1.5  107/kg) and a limited number (2-2.5
 106/kg) of highly T-cell depleted (CD3 10,000/kg) mobi-
lized peripheral blood (MPB)-HSC, after a myeloablative condi-
tioning of reduced extra-hematological toxicity. The rationale is: 1)
to provide sufﬁcient immunosuppression and a high anti-tumor
chemo-radiotherapeutic effect; 2) capacity of the MPB-HSC pro-
genitors for prompt engraftment; 3) low risk of CB rejection or
GVHD by the highly T cell depleted 3rd party cells; and 4)
competitive advantage of CB progenitors for long term engraft-
ment. Data of 28 (19M, 9F) adult high risk patients consecutively
transplanted in accordance with the protocol are as follows. Me-
dian age and weight 30 years (16-60) and 67 kg (43-87). CMV
serology was positive in 24/28. Cell content of the transplanted CB
units: TNC 2.37 107/kg (1.31-3.70), CD34 cells 0.11 106/kg
(0.035-0.37). Third party donor cells infused: CD34, 2.31 
106/kg (1.05-2.58); CD3, 2.5  103/kg (0.50-9.80). The 3rd
party donor was the mother (4), other haplo-identical relative (20),
or donors with no shared haplotype (4). Initially, post-transplant
circulating granulocytes were predominantly from the 3rd party
donor in all patients except the four receiving maternal MPB
CD34 cells. For the whole group, median time for ANC/l
500, CB-ANC/l 500 and full CB chimerism were 10 (9-36),
22 and 54 days, with maximum cumulative incidences of 0.93 for
the three variables; median time to platelets 20,000/l and
50,000/l, 32 and 60 days, with maximum cumulative incidences
of 0.75 and 0.70. Excluding the 4 patients who received maternal
MPB, the corresponding data are: median time to ANC/l 500,
CB-ANC/l 500 and full CB chimerism, 9.5 (9-17), 21 and 56
days, with maximum cumulative incidences of 1.00 for the ﬁrst two
variables and 0.96 for the third; median time to platelets
20,000/l and 50,000/l: 30 and 54 days, with maximal cumu-
lative incidences of 0.83 and 0.78. Adverse effects related to the 3rd
party cells have not been recognized. Incidences of GVHD and
relapses have been low. Main cause of morbidity has been oppor-
tunistic infections not related to neutropenia. There have been 8
deaths related to the procedure. These were due to toxicity (2),
graft failure (1), GVHD II (2) and opportunistic infection (3).
After a median follow up of 10 months (1-75) for all patients and
16 months (3-75) for the 20 living (9 surviving 2 years), 4 years
OS is 67% for the whole group and 86% for the 19 after excluding
the 5 older than 40 and the 4 with mothers as the 3rd party
donors.Our strategy makes CBT feasible as a ﬁrst choice option for
most patients of a wide age range and may allow additional immu-
notherapeutic maneuvers that are being assayed.
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INCIDENCE AND RISK FACTORS FOR EARLY SEVERE INFECTIONS AF-
TER UCB
Laughlin, M. Department of Medicine and Pathology, Case Western
Reserve University, School of Medicine, Cleveland, OH
Contributing factors to bacterial, viral, and fungal infections
occurring during the ﬁrst 100 days after unrelated UCB transplan-
tation share common features to that observed after allogeneic
transplantation with conventional marrow or PBSC grafts from
adult donors. These contributing factors include host variables
(age, underlying disease), type of conditioning (ablative, reduced
intensity), duration of neutropenia, acute GVHD incidence and
severity, and receipt of corticosteroids. In addition, preliminary
clinical data point to possible unique UCB graft features contrib-
uting to infections occurring at these early time points including:
UCB stem cell and accessory cell populations, and/or graft cell
dose impacting on kinetics of myeloid and lymphocyte reconstitu-
tion. UCB graft accessory cells exhibit selective developmental
defects in several critical cell function assays potentially contribut-
ing to innate and adaptive immune reconstitution as well as
aGVHD including: Toll-like receptor expression on antigen pre-
senting cells, neutrophil adhesion molecule surface expression, T
cell Th1 cytokine production. However, whether these defects are
recapitulated in the transplant recipient has yet to be fully exam-
ined. Clear interpretation of these preliminary clinical observations
of early infections after UCB transplantation in comparison with
the published literature in allogeneic transplantation incorporating
conventional adult-derived grafts is challenged by patient selection
variables, which remain high risk in the majority of UCB patients,
particularly in the adult setting. Taken together, a full understand-
ing of the incidence and risk factors for early severe infections after
UCB transplantation awaits large multi-institutional prospective
comparison studies with conventional marrow and PBSC from
adult donors. Results of these prospective comparison trials can
then be used to prepare evidence-based guidelines for the preven-
tion of infection after UCB transplantation.
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